Complicated urinary tract infection is generally associated with structural or neurological disorder that compromise the urinary tract or host defense. Some factors associated with complicated urinary tract infection include, urinary obstruction, immunosuppression, urinary retention, chronic renal failure, transplantation, pregnancy and catheters or other drainage devices. Uncomplicated urinary tract infection affects lower and upper part of bladder. It refers to infection of the normal urinary tract by nonresident infectious organisms.
The global urinary tract infection treatment market is estimated to account for US$ 10,170.8 Mn in terms of value and is expected to reach US$ 11,827.8 Mn by the end of 2027.
Global Urinary Tract Infection Treatment Market: Drivers
Approval and launch of new drugs is expected to propel growth of the global urinary tract infection market over the forecast period. For instance, in November 2019, Shionogi Inc. received the U.S. Food and Drug Administration approval for its Fetroja (cefiderocol), an antibacterial drug for treatment of complicated urinary tract infections in patients 18 years of age or older.
Global Urinary Tract Infection Treatment Market: Opportunities
R&D of in urinary tract infections is expected to offer lucrative growth opportunities for players in the global urinary tract infection treatment market. For instance, in October 2019, researchers from Aston University reported that a phosphate glass compound containing small amounts of zinc oxide (ZnO) can help eradicate the urinary tract infections that plague catheter patients.
Global Urinary Tract Infection Treatment Market: Restraints
Low price and short duration of therapy is expected to hinder growth of the global urinary tract infection treatment market. Mostly urinary tract infections are treated with antibiotics and almost all of these are available in generic form and the price of generic antibiotics is significantly low as compared to branded ones. Also, the duration of therapy is usually 1–2 week; unlike for blood pressure or heart disease in which patients need to take medicine throughout their life. These factors are impacting the market negatively.
The global urinary tract infection treatment market was valued at US$ 9,971.9 Mn in 2019 and is forecast to reach a value of US$ 11,827.8 Mn by 2027 at a CAGR of 2.2% between 2020 and 2027. Major factor driving the growth of global urinary tract infection treatment market during the forecast period include high prevalence of urinary tract infection, and availability of number of drugs.
Quinolones held dominant position in the global urinary tract infection treatment market in 2019, accounting for 37.7% share in terms of value, followed by Cephalosporin and Penicillin & Combinations, respectively. High use of quinolones in treatment of urinary tract infections is supporting growth of the segment.
Major players in the global urinary tract infection treatment market are focused on R&D of new therapies in order to expand their product portfolio. For instance, in August 2019, Venatorx Pharmaceuticals initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections.
Studies have found that preventative measures may not be effective in reducing the risk of catheter-associated urinary tract infection problems. For instance, in April 2020, researchers from Baylor College of Medicine and Veterans Affairs Medical Center, U.S., reported that catheter-associated urinary tract infection problems may occur even with preventative measures.
Global Urinary Tract Infection Treatment Market: Competitive Landscape
Major players operating in the global urinary tract infection treatment market include, Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG AstraZeneca Plc, Allecra Therapeutics, Healthy.io, Shionogi Inc., Spero Therapeutics, Inc., and Venatorx Pharmaceuticals.
Global Urinary Tract Infection Treatment Market: Key Developments
June 2020: Iterum Therapeutics plc, a clinical-stage pharmaceutical company, announced that sulopenem did not achieve statistical non-inferiority relative to ertapenem in its SUlopenem for Resistant Enterobacteriaceae (SURE) 2 clinical trial in complicated urinary tract infection (cUTI).